Biotechnology
Compare Stocks
2 / 10Stock Comparison
LQDA vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
LQDA vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.67B | $1712.35T |
| Revenue (TTM) | $69M | $0.00 |
| Net Income (TTM) | $-122M | $-168M |
| Gross Margin | 89.4% | — |
| Operating Margin | -155.0% | — |
| Forward P/E | 17.5x | — |
| Total Debt | $122M | $22M |
| Cash & Equiv. | $176M | $194M |
LQDA vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Liquidia Corporation (LQDA) | 100 | 457.6 | +357.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LQDA vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LQDA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.24
- Rev growth -20.0%, EPS growth -37.2%, 3Y rev CAGR 2.9%
- 280.9% 10Y total return vs DBVT's -87.0%
DBVT is the clearest fit if your priority is quality.
- 0.3% margin vs LQDA's -176.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -20.0% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs LQDA's -176.0% | |
| Stability / Safety | Beta 1.24 vs DBVT's 1.26 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +172.2% vs DBVT's +110.4% | |
| Efficiency (ROA) | -44.2% ROA vs DBVT's -89.0% |
LQDA vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LQDA vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LQDA and DBVT operate at a comparable scale, with $69M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $69M | $0 |
| EBITDAEarnings before interest/tax | -$106M | -$112M |
| Net IncomeAfter-tax profit | -$122M | -$168M |
| Free Cash FlowCash after capex | -$108M | -$151M |
| Gross MarginGross profit ÷ Revenue | +89.4% | — |
| Operating MarginEBIT ÷ Revenue | -155.0% | — |
| Net MarginNet income ÷ Revenue | -176.0% | — |
| FCF MarginFCF ÷ Revenue | -155.8% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +86.4% | +91.5% |
Valuation Metrics
Evenly matched — LQDA and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.7B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $3.6B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -25.47x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.54x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 262.27x | — |
| Price / BookPrice ÷ Book value/share | 43.06x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
DBVT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
DBVT delivers a -130.2% return on equity — every $100 of shareholder capital generates $-130 in annual profit, vs $-6 for LQDA. DBVT carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to LQDA's 1.58x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs LQDA's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -5.5% | -130.2% |
| ROA (TTM)Return on assets | -44.2% | -89.0% |
| ROICReturn on invested capital | -5.0% | — |
| ROCEReturn on capital employed | -84.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 1.58x | 0.13x |
| Net DebtTotal debt minus cash | -$54M | -$172M |
| Cash & Equiv.Liquid assets | $176M | $194M |
| Total DebtShort + long-term debt | $122M | $22M |
| Interest CoverageEBIT ÷ Interest expense | -4.63x | -189.82x |
Total Returns (Dividends Reinvested)
LQDA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LQDA five years ago would be worth $159,547 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, LQDA leads with a +172.2% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors LQDA at 77.2% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +34.6% | +4.9% |
| 1-Year ReturnPast 12 months | +172.2% | +110.4% |
| 3-Year ReturnCumulative with dividends | +456.3% | +19.7% |
| 5-Year ReturnCumulative with dividends | +1495.5% | -69.1% |
| 10-Year ReturnCumulative with dividends | +280.9% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +77.2% | +6.2% |
Risk & Volatility
LQDA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LQDA is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LQDA currently trades 90.6% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.26x |
| 52-Week HighHighest price in past year | $46.67 | $26.18 |
| 52-Week LowLowest price in past year | $11.85 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +90.6% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 65.2 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 252K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates LQDA as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 19.8% for LQDA (target: $51).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $50.67 | $46.33 |
| # AnalystsCovering analysts | 7 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
DBVT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). LQDA leads in 2 (Total Returns, Risk & Volatility). 1 tied.
LQDA vs DBVT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is LQDA or DBVT a better buy right now?
Analysts rate Liquidia Corporation (LQDA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LQDA or DBVT?
Over the past 5 years, Liquidia Corporation (LQDA) delivered a total return of +1495%, compared to -69.
1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: LQDA returned +280. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LQDA or DBVT?
By beta (market sensitivity over 5 years), Liquidia Corporation (LQDA) is the lower-risk stock at 1.
24β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 2% more volatile than LQDA relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 158% for Liquidia Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — LQDA or DBVT?
On earnings-per-share growth, the picture is similar: Liquidia Corporation grew EPS -37.
2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LQDA or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -931. 7% for Liquidia Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -866. 6% for LQDA. At the gross margin level — before operating expenses — LQDA leads at 58. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is LQDA or DBVT more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
07Which pays a better dividend — LQDA or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is LQDA or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Liquidia Corporation (LQDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
24), +280. 9% 10Y return). Both have compounded well over 10 years (LQDA: +280. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between LQDA and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.